August 25th 2025
Are we letting momentum outpace readiness?
Exploring the Promise of E7386 and Lenvatinib Combination Therapy in Endometrial Carcinoma
July 18th 2025Corina Dutcus, SVP, oncology global clinical development lead at Eisai, discusses the potential of the E7386 and lenvatinib combination to address unmet needs in second-line treatment for endometrial carcinoma patients.
LEAP-002 Study Shows Five Year Survival Consistency in Unresectable Liver Cancer
July 15th 2025Corina Dutcus, SVP, oncology global clinical development lead, Eisai, highlights how consistent survival data from the LEAP-002 study reaffirms lenvatinib’s value in first-line treatment of unresectable hepatocellular carcinoma.
FDA Accepts New Drug Application for Merck’s Doravirine/Islatravir in HIV
July 14th 2025The new drug application is supported by 48-week data from the Phase III MK-8591A-051 and MK-8591A-052 trials, which showed that the doravirine/islatravir combination was non-inferior to both baseline antiretroviral therapy and to bictegravir/emtricitabine/tenofovir alafenamide in treating HIV.
Johnson & Johnson Seeks Expanded FDA Approval of Caplyta for Relapse Prevention in Schizophrenia
July 8th 2025The supplemental New Drug Application is supported by Phase III data, which showed Caplyta significantly prolonged time to relapse compared to placebo and reduced the risk of relapse by 63% in patients with schizophrenia.
AbbVie Targets Post-ASCO Growth with New Oncology Trial Momentum
June 27th 2025Pedro Valencia, VP, asset strategy, leadership, oncology, AbbVie, outlines how the company is accelerating development across lung, gastrointestinal, and ovarian cancers following ASCO 2025, with a focus on advancing antibody drug conjugates and expanding late-stage studies.
The Role of Patient Advocacy in Shaping AbbVie's Cancer Therapies
June 26th 2025Pedro Valencia, VP, asset strategy leadership, oncology, AbbVie, explains how the company partners with patient advocacy groups to identify unmet needs and prioritize patient-centered benefits in the development of innovative cancer therapies.
Pfizer’s Hympavzi Demonstartes Significantly Reduced Annualized Bleeding Rates in Hemophilia
June 26th 2025Results from the Phase III BASIS trial show that once-weekly subcutaneous Hympavzi reduced annualized bleeding rates by 93% compared to on-demand treatment with bypassing agents in patients with hemophilia A or B.
Early Data on ABBV-706 Suggests New Hope for Neuroendocrine Tumor Patients
June 25th 2025Pedro Valencia, VP, asset strategy leadership, oncology, AbbVie, discusses how early data from ABBV-706 shows up to 50% response rates in rare neuroendocrine tumors, offering a potential advance over traditional chemotherapy.
Teva’s Ajovy Maintains Long-Term Effectiveness in Preventing Chronic, Episodic Migraine
June 25th 2025Final results from the Phase IV PEARL trial show that 66% of patients treated with Ajovy for episodic migraine and more than half of those treated for chronic migraine who responded during the first six months maintained a ≥50% reduction in monthly migraine days.
AbbVie Positions Temab-A ADC for Tumor-Agnostic Use in Multiple Cancers
June 24th 2025Pedro Valencia, VP, asset strategy leadership, oncology, AbbVie, explains how the company is advancing Temab-A across multiple tumor types targeting c-Met, with the goal of establishing it as a pipeline-in-a-molecule.